TAK-999-3001: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis03/26/2024 - 03/26/2029 (PI)
Takeda Pharmaceuticals
K-001-201: A PHASE 2, MULTICENTER, PLACEBO-CONTROLLED,
RANDOMIZED, DOUBLE-BLIND, 48-WEEK STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF COMBINATION
THERAPY OF K-877-ER AND CSG452 IN PATIENTS WITH
NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH)
WITH L08/08/2024 - 08/08/2027 (PI)
Kowa Research Institute, Inc.
Global Longitudinal Assessment of Nonalcoholic Fatty Liver Disease (NAFLD) using Magnetic Resonance Elastography GOLD-MINE Study Protocol06/15/2020 - 08/03/2027 (Multi-PI)
PI:
Arpan Mohanty, MBBSThe Regents of the University of Calif., U.C. San Diego Astrazeneca Pharm
NN9500-7730: Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease05/29/2024 - 05/29/2027 (PI)
Novo Nordisk
MGL-3196-19: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)01/24/2024 - 01/24/2027 (PI)
Madrigal Pharmaceuticals, Inc.
Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA)10/16/2024 - 01/15/2027 (PI)
Bristol-Myers Squibb Foundation
ESSENCE: The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis-NN9931-455311/05/2021 - 11/05/2026 (PI)
Novo Nordisk
TAK-999-3002: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F1 Fibrosis08/30/2024 - 08/30/2026 (PI)
Takeda Pharmaceuticals
LINC: Leveraging Informatics for NAFLD Care12/01/2019 - 12/31/2024 (PI)
Gilead Sciences
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating …05/16/2017 - 05/31/2024 (PI)
Intercept Pharmaceuticals, Inc.
Showing 10 of 13 results.
Show All Results
Piloting a Standardized Care Pathway to Improve Risk Stratification and Management of patients with Nonalcoholic Fatty Liver Disease (NAFLD)"12/01/2022 - 11/30/2023 (PI)
The Kinetix Group
Unraveling Racial Disparities in Portal Hypertension: A Clinical Spectroscopic and SNP Approach03/02/2021 - 12/31/2022 (Multi-PI)
PI:
Arpan Mohanty, MBBSBaylor College of Medicine NIH NIMHD7R21MD013631-02
Spectroscopic Interrogation of Upper Gastrointestinal Mucosa: A Less Intrusive Measure of Hepatic…07/01/2018 - 03/31/2020 (PI)
American Association for the study of Liver Diseases
Spectroscopic interrogation of Upper Gastrointestinal Mucosa: A Less Intrusive Measure of Hepatic Venous Pressure Gradient07/01/2018 - 06/01/2019 (PI)
American Association for the Study of Liver Diseases (AASLD)
Advanced/ Transplant Hepatology Training Award07/01/2016 - 06/01/2017 (PI)
American Association for the Study of Liver Diseases (AASLD)